Is it better to treat early to control the development of symptoms, or wait until symptoms worsen and then start JAK inhibitor therapy?
Recent Video
| 
Most Popular
Specialties :                    Search :
MPN Highlights - ASH 2017
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera (PV)...
The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis among Older Patients with Polycythemia Vera
Validation of the Myelofibrosis Secondary to PV and ET – Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia..
Characteristics of Patients with Chronic Phase Myelofibrosis and Elevated Blasts (5-9%), and the Effect of JAK2 Inhibitor Ruxolitinib
Myelofibrosis (MF) Leukemic Transformation (LT) in the Era of Ruxolitinib and Genomics: Characteristics and Outcomes
Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea
Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated With Hydroxyurea in the United States: an Analysis...
Patient-Reported Symptom Burden and Peripheral Blood Counts Among Patients with Polycythemia Vera: An Analysis From the REVEAL Study
Sotatercept (ACE-011) Alone and with Ruxolitinib in Patients with MPN-associated Myelofibrosis (MF) and Anemia with Ruxolitinib or Hydroxyurea
Phase I/II Trial of Glasdegib in Patients With Primary or Secondary Myelofibrosis
Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Phase 3 Trial of Momelotinib versus Ruxolitinib in JAK Inhibitor Naive Patients with Myelofibrosis
Mechanisms of Resistance to 5-Azacytidine/Decitabine in MDS-AML and Pre-Clinical In Vivo Proof of Principle of Rational Solutions to Extend Response
Radioactive Iodine Treatment of Thyroid Cancer and Risk of Myelodysplastic Syndromes
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks
A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with MDS
HRQoL and Efficacy with Myelofibrosis Patients in the Phase III Persist-1 Trial of Pacritinib Vs BAT
Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell
First Multicenter, Randomized Phase 3 Study in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Alisertib Versus Investigator
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with AML and High Risk MDS
5-Azacytidine in Combination with Ruxolitinib As Therapy for Patients with Myelodysplastic/Myeloproliferative Neoplasms
Impact of Eltrombopag on Expansion of Clones with Somatic Mutations in Refractory Aplastic Anemia
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated AML
Prognostic Impact of Molecular Mutations in AML and MDS on Allogeneic Hematopoietic Cell Transplant Outcomes: Adverse Impact of TET2 Mutations
Safety of Lenalidomide 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients with Lower-Risk MDS
A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML)
SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML
Outcomes in Patients with Myelofibrosis: Pacritinib Vs BAT in the Phase III Persist-1 Trial
PERSIST-1 phase III study of pacritinib versus BAT in PMF, PPV-MF, or PET-MF
Clinical Discussion Regarding Choice of Therapy for Polycythemia Vera (PV)
Clinical Discussion Regarding Polycythemia Vera (PV) and Thrombosis
Biomarker and Surrogate Targets for Successful Therapy in Polycythemia Vera (PV)
How Do You Treat PV Patients That Fail Hydroxyurea (HU)?
What is the Current Standard of Care in Treating Polycythemia Vera (PV)?
What Would You Suggest for a PMF Patient on Ruxolitinib Who Has Refractory Anemia, but Only Modest Spleen/Symptom Response?
Do You Attempt to Correct Cytopenias Before Giving Ruxolitinib?
Are MF Patients with RBC Transfusion-Dependent Anemia Considered Candidates for Ruxolitinib Therapy?
Do MF Patients with Low Platelets Have a Different Disease Course/Burden Relative to Those with Normal/High Platelets?
For an HU-Refractory PV Patient on Ruxolitinib, How Would Your Treat after He/She Progresses to Post-PV MF?
After PV Progression, Which Patients Should Receive Second-Line Ruxolitinib vs Interferon (IFN)?
What Steps Do You Take for Differential Assessment/Treatment of Debilitating Fatigue in Patients with PV?
Does Development of HU-Refractory PV Increase a Patient’s Risk for Thrombosis/Cardiovascular Events? Why?
Would Pregnancy Change the Management of Young Woman with Low-Risk PV? Do You Alter Antithrombotic Therapy?
Should Patients Continue to Receive Anti-Platelet Therapy/Anticoagulation after Progression to Post-PV MF?
Does Baseline Platelet Count Determine the Starting Dose of Ruxolitinib for HU-Refractory/Intolerant PV (Like It Does for MF)?
Should JAK2V617F Allele Burden Be Monitored in Patients with PV?
In Patients with PV, What Clinical Triggers Would Lead You to Perform a Bone Marrow Biopsy?
What Factors Do You Use to Determine If an MF Patient Is, or Is Not, Benefitting from Long-Term Ruxolitinib Treatment?
How Long Do MF Patients Typically Stay on Ruxolitinib Therapy? What Are the Main Reasons for Discontinuation?
How Often Do You Monitor CBC after a Patient Reaches His/Her Stable Ruxolitinib Dose?
Do Post-PV MF and Primary MF have Different Clinical Courses and/or Prognosis?
Is the Rate of MPN Leukemic Transformation (ie, BP-MPN) Affected by Prior Therapy?
Are There Certain Genetic Alterations That May Help Identify Patients at Risk for Imminent Leukemic Transformation?
For Hematopoietic Cell Signal Transducer (HSCT) Candidates with Advancing MF, What are Their Chief Reasons for Electing Not to Undergo Transplant?
Do Patients Ever Present with >5% Peripheral Blasts at Diagnosis?
If Peripheral Blasts Increase While on Ruxolitinib, is That Considered Treatment Failure?
Are There Different Types of Blasts in the Peripheral Blood, and What Do They Mean for a Patient with an MPN?
Do You Routinely Monitor Patients for Signs of Leukemic Transformation (eg, JAK2 Allele Burden)?
Does Progression to Accelerated or Blast-Phase MF Increase Patient
Introduction to the ImpactLive MPN program
Dr. Claire Harrison Discusses Where We Stand in the MPN Space Today
Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis
The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera
Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea
Dr. Srdan Verstovsek Discusses Approval of Ruxolitinib as a New Therapy for Patients with Polycythemia Vera
Loss of Response While Being Treated with a JAK Inhibitor
Atypical Infections While Being Treated with a JAK Inhibitor
Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis
First Choice of Therapy for (non-MF) MPN Diagnosed Patients.
2nd Line Therapy for Patients Diagnosed with Polycythemia Vera (PV)
Initiating Treatment for Early Stage Myelofibrosis (MF) Disease
Interim Results on Fedratinib - ASH 2013 - Claire Harrison, DM, FRCP
A Pooled Overall Survival Analysis of The COMFORT Studies - ASH 2013 - Claire Harrison, DM, FRCP
Phase II study of a JAK 1 inhibitor (INCB39110) in patients with MF - John Mascarenhas, M.D.
Modified Dose Escalation of Ruxolitinib: A Feasible Therapeutic Approach in the Management of MF - ASH 2013 - Ramon Tiu, M.D
Inhibition of JAK-STAT Pathway As a Therapeutic Option For MF Associated Pulmonary Hypertension - Ramon Tiu, M.D.
What are the most important factors to consider when selecting ruxolitinib dosage?
What is the standard of care for first-line treatment of JAK (-) MF?
Is it better to treat early to control the development of symptoms, or wait until symptoms worsen and then start JAK inhibitor therapy?
Is JAK inhibitor therapy beneficial in MF patients who have only mild symptoms and minimal splenomegaly?
Typical Duration of Therapy with Ruxolitinib
Reasons People go off Ruxolitinib
Discussion on Combination Treatment Strategies
Discussion on Patients with Anemia who are Being Treated with Ruxolitinib
Treating Patients with Splenomegaly who are Already Anemic
Treating Patients with Ruxolitinib who have High Platelet Counts
Treating Patients with Ruxolitinib who have Low Platelet Counts
Titration with Ruxolitinib – Titrate up or down?
JAK Inhibitors in Patients with Mutated JAK and Wild-type JAK – Equally Efficacious?
Discussion on the Dysregulation of the JAK STAT Pathway
Treatment options for Patients with PMF (wild-type JAK)
Early Signs and Symptoms in MPNs
Main Reasons for Patient Referral to an MPN Specialist
Other Agents Nearing Approval for the Treatment of MPN
Current Combination Strategies in the Clinical Setting
Best Treatment Approach in Patients with Low-Risk MF
Most Frequent Adverse Reactions in Patients with Ruxolitinib
Therapy Interruption in Patients on Ruxolitinib
Discussion on QOL Issues
Short-Term and Long-Term Concerns in Treating Patients with MF
Discussion on MPN Therapies
Survival Benefit of Ruxolitinib to Best Available Therapy – COMFORT II Trial
New Therapies in Treating MPNs
Discussion on Disease Modifying Therapies
Discussion on QOL Issues
What do Pharmacists Need to Know
Interruption of Therapy with Ruxolitinib
Storing and Handling of Ruxolitinib
Treatment Issues for First Time Patients on Ruxolitinib
Platelet Count and Proper Dosing of Ruxolitinib in New Patients
Titration with Ruxolitinib – Titrate up or down?
Side Effect Profile Issues
Treatment Strategies – Do They Change with Age?
Starting Dose in Patients Who are Frail or Elderly
Process in Determining Starting Dose for Ruxolitinib
Discussion on CYP3A4 Inhibitors and CYP3A4 Inducers
Lifestyle Modifications in Patients Diagnosed with MPNs
Discussion on Eating Patterns in Patients Diagnosed with MPNs
Discussion on Troublesome Symptoms in Patients Diagnosed with MPNs
How do you Address Issues with Pain Management in Patients Diagnosed with MPNs?
How do you Manage Itching in Patients Diagnosed with MPNs?
What Type of Monitoring/Surveillance is Done in Patients Diagnosed with MPNs
Primary Care Physicians – What do They Need to Know?
Primary Care Physicians – When do you Bring in a Specialist?


MPNUniversity.tv is a member of the Oncology.TV family of oncology medical education websites. MPNUniversity.tv offers specialists, primary care physicians, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), news and information about Myeloproliferative Neoplasms (MPNs).